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a b s t r a c t
Background: Geriatric conditions, such as frailty and cognitive impairment, are prevalent in older patients
with atrial fibrillation (AF). We examined the prognostic value of geriatric conditions for predicting 1-
year mortality and bleeding events in these patients.
Methods: SAGE (Systematic Assessment of Geriatric Elements)-AF study is a multicenter cohort study
which enrolled individuals (mean age 75 years, 48% women, 86% taking oral anticoagulation) 65 years
and older with AF and CHA2DS2 -VASc score of 2 or higher from clinics in Massachusetts and Georgia,
USA between 2016 and 2018. A six-component geriatric assessment included validated measures of
frailty, cognitive function, social support, depressive symptoms, vision, and hearing was performed at
baseline. Study endpoints included all-cause mortality and clinically relevant bleeding.
Results: At 1 year, 1,097 (96.5%) individuals attended the follow up visit, 44 (3.9%) had died, and 56 (5.1%)
had clinically relevant bleeding. After adjustment for demographic and clinical factors, social isolation
(odds ratio [OR] 1.69, 95% confidence interval [CI]: 1.01–2.84), depression (OR 1.94, 95% CI: 1.28–2.95)
and frailty (OR 2.55, 95% CI: 1.55–4.19) were significantly associated with the composite endpoint of
death or clinically relevant bleeding. After multivariable adjustment, depression (OR 1.79, 95% CI 1.09–
2.93) and frailty (OR 2.83, 95% CI 1.55–5.17) were significantly associated with clinically relevant bleed-
ing.
Conclusions: Social isolation, depression, and frailty were prognostic of dying or experiencing clinically
relevant bleeding during the coming year in older men and women with AF. Assessing geriatric impair-
ments merits consideration in the care of these patients.
 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Atrial fibrillation (AF) is prevalent among older men and
women and increases their risk for stroke [1]. Oral anticoagulation
is the cornerstone of stroke prevention in patients with AF who are
at elevated stroke risk [2] although it also increases their risk for
bleeding [3]. Physicians are commonly confronted with the
dilemma that patients at high stroke risk are also more prone to
bleeding.
Physical, sensory, cognitive, and psychosocial impairments are
common in older men and women with AF [4]. These conditions
include, but are not limited to, frailty, hearing and vision loss, cog-
nitive impairment, depression, and social isolation. Depression has
been previously associated with an increased risk for stroke and
bleeding in patients with AF who were treated with warfarin [5].
However, there has been no systematic evaluation about the prog-
nostic value of a comprehensive set of geriatric conditions to
important clinical outcomes, including total mortality and bleed-
ing, among older individuals with AF.
Using data from the SAGE-AF study of older men and women
with AF [4], we examined the association between several system-
ically measured geriatric conditions and the risk of dying as well as
experiencing episodes of bleeding during a one-year follow up.
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1. Methods
1.1. Study sample
The details of the SAGE-AF study have been previously
described [4,6]. In brief, the inclusion criteria consisted of the
following: 1) have an ambulatory visit at one of 4 Central
Massachusetts practices (University of Massachusetts Memorial
Health Care internal medicine, cardiology, or electrophysiology,
Heart Rhythm Associates of Central Massachusetts), 1 practice in
Eastern Massachusetts (Boston University cardiology), or 2 prac-
tices in Central Georgia (Family Health Center and Georgia
Arrhythmia Consultants), 2) AF is present on an electrocardiogram
or Holter monitor or is noted in any clinic note or hospital record),
3) be 65 years or older, and 4) have a CHA2DS2VASC [7] risk
score  2. Participants were not eligible if they had an absolute
contraindication to the receipt of oral anticoagulation, if they had
an indication for oral anticoagulation other than AF (i.e., mechani-
cal heart valve), if they could not provide informed consent, if they
did not speak English, if they had a planned invasive high bleeding
risk procedure, if they were incarcerated, or if they were unwilling
or unable to participate in planned follow-up visits. The study
enrollment and the assessment of geriatric conditions were inde-
pendent of the timing of initiating anticoagulation therapy.
The follow-up visit was performed at 1 year after study enroll-
ment. All participants provided informed written consent. Study
protocols were approved by the Institutional Review Boards at
the University of Massachusetts Medical School, Boston University,
and Mercer University.
1.2. Data abstraction
Trained study staff abstracted pertinent patient socio-
demographic and clinical data from the medical record including
participants’ age, sex, race, insurance type, comorbidities relevant
to stroke and bleeding risk (i.e.,., diabetes, hypertension, heart fail-
ure, anemia, chronic kidney disease), and cardiovascular treat-
ments (i.e., use of anti-platelets). Relevant laboratory data,
including serum creatinine, hemoglobin, and international normal-
ized ratio values (over the past 4 weeks), were also abstracted.
1.3. Assessment of geriatric conditions
Validated measures were used to assess the presence of 6 geri-
atric conditions: frailty, cognitive dysfunction, social support,
depressive symptoms, and vision and hearing impairment. Frailty
was assessed by the Cardiovascular Health Survey frailty scale
[8]. Its components include weight loss/shrinking, exhaustion,
low physical activity, slow gait speed, and weakness. Each compo-
nent receives a point and the scale ranges from 0 to 5 (0: not frail,
1–2: pre-frail, 3 or more: frail). Cognition was assessed by the
Montreal Cognitive Assessment Battery (MoCA) [9], a 30-item
screening tool validated to detect mild cognitive impairment.
Higher scores indicate better cognitive function, with a score < 23
indicating cognitive impairment [10]. Instead of the traditional
cutoff of < 26 in MoCA, we chose the cutoff at < 23. The lower cutoff
was chosen because it was previously shown to correspond to the
cutoff for mild cognitive impairment and dementia (<27) in the
most widely used Mini-Mental State Examination (MMSE) score
[10] with sensitivity ranging from 71% to 78% and specificity 88%
to 96% [11]. The social support available to participants was
assessed by a 5-item modified version of the Social Support Scale
and the 6-item Social Network Scale [12]. Lower scores indicate
less social support and a score of < 12 indicates social isolation.
The Patient Health Questionnaire (PHQ-9) was used to assess
patient’s depressive symptoms [13] with a score  5 indicating
high depressive symptoms. Visual and hearing impairment were
self-reported and categorized as either impaired or otherwise.
1.4. Assessment of death and bleeding events
For participants who died during the 1-year follow-up, the date
of death was collected from the medical record and review of death
certificates by an adjudication committee comprised of physicians.
Self-reported episodes of bleeding were obtained from scripted
interviews and were graded as either major, clinically relevant
non-major, and minor according to the International Society on
Thrombosis and Hemostasis scale [14]. Major bleeding included
fatal bleeding, symptomatic bleeding in a critical area or organ
(e.g., intracranial, spinal, ocular, pericardial, articular, retroperi-
toneal, or intramuscular with compartment syndrome), or bleed-
ing that resulted in a fall in hemoglobin of 2 g/dL, leading to
transfusion of  2 units of whole blood. Clinically relevant, non-
major bleeding included all cases of overt bleeding not meeting
our criteria for the presence of major bleeding, but required med-
ical intervention (e.g., macroscopic hematuria), an unscheduled
contact (visit or telephone) with a physician, temporary interrup-
tion of anticoagulation, pain (e.g., hematoma), or impairment of
daily activities (e.g., inability to walk due to a hematoma). Episodes
of minor bleeding included all cases of bleeding (e.g., minor bruis-
ing, epistaxis) not classified as clinically relevant or major bleeding.
We defined three bleeding outcomes which are progressively
more severe and less inclusive. They were: 1) any bleeding, which
includes major, clinically relevant non-major, and minor bleeding
events; 2) clinically relevant bleeding, which includes major and
clinically relevant non-major bleeding events; and 3) major bleed-
ing, which includes only major bleeding events.
To address the issue of competing risk of death and bleeding, we
also defined a composite outcome which included death and
clinically relevant bleeding.
1.5. Statistical analysis
The sociodemographic and clinical characteristics of study
participants were compared according to the presence of any
bleeding events and/or mortality using analysis of variance for
continuous variables and the v2 test for categorical variables.
In the analysis of the composite outcome of death and clinically
relevant bleeding, we carried out a logistic regression analysis in
which several potentially confounding variables were controlled
for. Model 1 controlled for age, sex, race, and education. Model 2
additionally controlled for patient’s history of bleeding, heart fail-
ure, carotid artery disease, peripheral vascular disease, hyperten-
sion, diabetes, anemia, lung disease, renal disease, and the
placement of an implantable device. Model 3 further controlled
for HASBLED score, systolic blood pressure, anticoagulation use,
and antiplatelet use.
The association of geriatric conditions with all-cause mortality
and bleeding events was also examined using these outcomes as
separate end points by logistic regression analysis. In analyses with
death as the outcome, model 1 controlled for age, sex, race, and
education. Model 2 additionally adjusted for patient’s history of
bleeding, heart failure, peripheral vascular disease, hypertension,
diabetes, anemia, lung disease, renal disease, implantable device,
and anxiety. Because confounders in the analysis with bleeding
as the outcome may differ from those in the analysis with death
as the outcome, we built different multivariable models for bleed-
ing endpoints: model 1 controlled for age, sex, and race. Model 2
additionally adjusted for education, history of bleeding, and
HASBLED score. Model 3 additionally adjusted for systolic blood
pressure, anticoagulation use, and antiplatelet use. We additionally
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introduced the variable of time in the therapeutic range as a
surrogate for quality of anticoagulation control to model 3 among
participants on warfarin.




A total of 1,244 participants completed their baseline examina-
tion. At 1 year, 1,097 (96.5%) individuals attended the follow up
visit and 44 patients (3.9%) had died since the time of the baseline
examination. At the baseline interview, study participants were on
average 75.3 (±7.0) years old and 47.9% were women. Physical,
cognitive, and psychosocial impairment were relatively common:
frailty (13.3%), hearing impairment (35.4%), visual impairment
(33.3%), cognitive impairment (40.6%), depressive symptoms
(27.4%), and social isolation (13.0%).
Table 1 summarizes the baseline characteristics of the 1,137
individuals according to the composite outcome of death or devel-
opment of a clinically relevant bleeding episode (major + clinically
relevant non-major) at 1 year. Individuals who developed the com-
posite outcome (n = 122, 10.7%) were more likely to be female and
frail than participants who did not experience this endpoint. These
individuals were also more likely to have a history of major bleed-
ing, heart failure, carotid disease, diabetes, anemia, renal disease,
and an implantable cardiac device. They were more likely to have
been treated with Plavix and had higher CHADSVASC and HASBLED
scores as compared with individuals who did not develop the com-
posite outcome.
2.2. Study end points and follow up
At 1 year, 44 (3.9%) individuals had died. Major bleeding
occurred in 25 (2.2%) individuals, clinically relevant non-major
bleeding in 56 (4.9%), and minor bleeding in 585 (51.5%). There
were 2 (0.2%) bleeding-related deaths.
2.3. Geriatric conditions and composite outcome (death or clinically
relevant bleeding)
In examining the prognostic value of geriatric conditions in rela-
tion to death or clinically relevant bleeding during the first year of
study follow up, a greater risk of the composite outcome was
observed in individuals with cognitive impairment (14.5% versus
8.2%), depressive symptoms (15.8% versus 8.8%), frailty (23.2%
versus 8.8%), and social isolation (16.2% versus 9.9%) than among
those without these conditions. After adjusting for several demo-
graphic characteristics and comorbidities of prognostic importance,
depression, frailty and social isolation remained significantly asso-
ciated with all-cause mortality or clinically relevant bleeding
(Table 2).
We also examined whether the use of anti-depressants was
associated with a worse clinical outcome. There were 200 (17.6%)
participants who reported taking anti-depressants. The use of
anti-depressants was not associated with the composite endpoint
of death or bleeding (p = 0.70).
2.4. Geriatric conditions and all-cause mortality
We next examined the association of the 6 geriatric conditions
and all-cause mortality during the first year of study follow up. A
greater risk of dying was observed in individuals with cognitive
impairment (6.1% versus 2.4%), depressive symptoms (6.4% versus
2.9%), frailty (10.6% versus 2.8%), and social isolation (7.4% versus
3.3%) than among those without these conditions. After adjusting
for several demographic characteristics and comorbidities, social
isolation remained significantly associated with 1-year mortality
(Table 3).
2.5. Geriatric conditions and bleeding
Bleeding outcomes were examined in a systemic manner:
clinically relevant bleeding, any bleeding, and major bleeding were
assessed separately.
We first examined this association in relation to clinically
relevant bleeding events (major + clinically relevant non-major).
A significantly higher risk of clinically relevant bleeding was
observed in individuals with depressive symptoms (9.9% versus
6.5%) and frailty (13.9% versus 6.4%) than among those without
these conditions. After adjusting for a variety of patient demo-
graphic, clinical, and treatment characteristics, depressive symp-
toms and frailty remained significantly associated with an
increased risk of a clinically relevant bleeding episode (Table 4).
We also examined any bleeding as the outcome (major + clini-
cally relevant non-major bleeding + minor bleeding). Consistent
with our previous finding, depressive symptoms and frailty were
significantly associated with the development of any bleeding epi-
sode during the following year after adjusting for several poten-
tially confounding variables (Supplementary material: Tables S1).
Lastly, major bleeding was the most severe but least common
(2.3%) bleeding outcome. None of the geriatric conditions was
significantly associated with major bleeding in the multivariable
adjusted regression models (Supplementary material: Tables S2).
Since age may impact the association between various geriatric
conditions and clinical outcomes, we performed stratified analyses
according to age (<75 years old versus  75 years old). There was
no material difference in the association between geriatric condi-
tions and the composite endpoint of clinically relevant bleeding
and death by age with the exception of the factor of visual impair-
ment. Specifically, vision impairment was significantly associated
with the composite endpoint of clinically relevant bleeding and
death in older (>=75 years) participants (adjusted OR 1.93, 95%
CI: 1.05–3.55) but not in younger participants (<75 years)
(adjusted OR 0.99, 95% CI: 0.50–1.95) (Supplementary material:
Tables S3).
Since the quality of anticoagulation can be related to bleeding
and death, we additionally introduced the variable of time in the
therapeutic range to regression model 3 in Table 2 among partici-
pants on warfarin. After controlling for this additional variable,
depression (OR 1.48, 95% CI 0.79–2.75), frailty (OR 1.63, 95% CI
0.75–3.57), and social isolation (OR 1.92, 95% CI 0.85–4.34) were
no longer significantly associated with the composite endpoint of
bleeding and death.
3. Discussion
In a large cohort of older persons with AF, 86% of whom were
treated with oral anticoagulants, we systematically measured
several physical, cognitive, and psychosocial conditions that are
common in older men and women with AF. We showed that
depressive symptoms, frailty, and social isolation were associated
with an increased risk of dying or experiencing clinically relevant
bleeding in older patients with AF during our 1-year follow-up
period. When death and bleeding events were examined sepa-
rately, social isolation was associated with all-cause mortality
while depressive symptoms and frailty were associated with the
development of clinically relevant bleeding.
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Table 1
Characteristics of older adults with atrial fibrillation according to death or clinically relevant bleeding episode within 1 year.
Overall Death or clinically relevant bleed P value
Yes No
(n = 1137) (n = 122) (n = 1015)
Age 75.3 (7.0) 76.2 (7.0) 75.2 (7.0) 0.11
65–74 years 586 (51.5%) 54 (44.3%) 532 (52.4%) 0.23
75–84 years 412 (36.2%) 50 (41.0%) 362 (35.7%)
>85 years 139 (12.2%) 18 (14.8%) 121 (11.9%)
Female 545 (47.9%) 45 (36.9%) 500 (49.3%) <0.01
Non-Hispanic white 976 (85.9%) 99 (81.2%) 877 (86.5%) 0.11
Education < College graduate 629 (56.1%) 69 (57.0%) 560 (56.0%) 0.83
>= College 492 (43.9%) 52 (43.0%) 440 (44.0%)
Site Massachusetts 892 (78.5%) 87 (71.3%) 805 (79.3%) 0.05
Insurance Commercial/HMO/PPO 209 (18.4%) 18 (14.8%) 191 (18.8%) 0.44
Medicare 816 (71.8%) 94 (77.1%) 722 (71.1%)
Other 108 (9.5%) 10 (8.2%) 98 (9.7%)
Frailty Frail (>= 3 criteria) 151 (13.3%) 35 (28.7%) 116 (11.4%) <0.001
Pre-frail (1 or 2 criteria) 602 (53.0%) 67 (54.9%) 535 (52.7%)
Smoking Never 538 (47.3%) 53 (43.4%) 485 (47.8%) 0.65
Ever 567 (50.0%) 65 (53.3%) 502 (49.5%)
Bleeding history Major bleeding 212 (18.7%) 39 (32.0%) 173 (17.0%) <0.001
Gastrointestinal bleeding 122 (57.6%) 27 (69.2%) 95 (54.9%) 0.1
Bleeding requiring transfusion 37 (17.6%) 9 (23.7%) 28 (16.3%) 0.29
Intracranial bleeding 13 (6.2%) 3 (7.9%) 10(5.8%) 0.63
Medical history Alcohol use 362 (31.8%) 40 (32.8%) 322 (31.7%) 0.81
Anemia 356 (31.3%) 50 (41.0%) 306 (30.2%) <0.05
Carotid disease 122 (10.7%) 21 (17.2%) 101 (10.0%) <0.05
Myocardial infarction 217 (19.1%) 25 (20.5%) 192 (18.9%) 0.68
Dyslipidemia 914 (80.4%) 103 (84.4%) 811 (79.9%) 0.22
Hypertension 1024 (90.1%) 107 (87.7%) 917 (90.3%) 0.37
Heart failure 416 (36.6%) 69 (56.6%) 347 (34.2%) <0.001
Implanted cardiac device 380 (33.4%) 60 (49.2%) 320 (31.5%) <0.001
Lung disease 287 (25.2%) 39 (32.0%) 248 (24.4%) 0.08
Peripheral vascular disease 161 (14.2%) 20 (16.4%) 141 (13.9%) 0.46
Renal disease 317 (27.9%) 44 (36.1%) 273 (26.9%) <0.05
Medical history Stroke 112 (9.9%) 12 (9.8%) 100 (9.9%) 0.99
Type 2 diabetes 309 (27.2%) 54 (44.3%) 255 (25.1%) <0.001
Anti-platelet Aspirin 400 (35.2%) 49 (40.2%) 351 (34.6%) 0.23
Clopidogrel 70 (6.2%) 13 (10.7%) 57 (5.6%) <0.05
Anticoagulant 976 (85.9%) 109 (89.3%) 867 (85.4%) 0.24
Type of Oral anticoagulant* Direct oral anticoagulant 420 (43.0%) 42 (38.2%) 378 (43.6%) 0.28
Warfarin 557 (57.0%) 68 (61.8%) 489 (56.4%)
CHADSVASC 4.4 (1.6) 4.8 (1.7) 4.3 (1.6) <0.01
HASBLED 3.2 (1.1) 3.4 (1.1) 3.2 (1.1) <0.05
Creatinine (milligrams per deciliter) 1.1 (0.5) 1.3 (0.9) 1.1 (0.5) <0.01
Hemoglobin (grams per deciliter) 13.1 (1.8) 12.9 (2.0) 13.2 (1.8) 0.16
Platelet (  109 per liter) 210.2 (71.0) 213.5 (84.5) 209.8 (69.2) 0.63
Time in therapeutic range (in warfarin users) 0.49 (0.42) 0.51 (0.42) 0.49 (0.42) 0.65
Data were presented as n (%) or mean (standard deviation).
*among those on anticoagulants.
Table 2




Unadjusted Model 1 Model 2 Model 3
Cognitive impairment Yes 462 (40.6%) 67 (14.5%) 1.91 (1.31, 2.79) 1.82 (1.20, 2.77) 1.45 (0.94, 2.24) 1.47 (0.95,2.28)
No 675 (59.4%) 55 (8.2%) Reference
Depression Yes 311 (27.4%) 49 (15.8%) 1.93 (1.31, 2.85) 2.14 (1.43, 3.18) 1.93 (1.28, 2.93) 1.94 (1.28, 2.95)
No 826 (72.7%) 73 (8.84%) Reference
Frailty Yes 151 (13.3%) 35 (23.2%) 3.12 (2.01, 4.83) 3.53 (2.21, 5.62) 2.54 (1.55, 4.17) 2.55 (1.55, 4.19)
No 986 (86.7%) 87 (8.8%) Reference
Hearing impairment Yes 402 (35.4%) 42 (10.5%) 0.96 (0.64, 1.42) 0.84 (0.55, 1.27) 0.85 (0.55, 1.30) 0.84 (0.55, 1.29)
No 735 (64.6%) 80 (10.9%) Reference
Social isolation Yes 148 (13.0%) 24 (16.2%) 1.76(1.08, 2.86) 1.77 (1.08,2.90) 1.66 (1.00,2.78) 1.69 (1.01,2.84)
No 989 (87.0%) 98 (9.9%) Reference
Vision impairment Yes 294 (25.9%) 39 (13.3%) 1.40 (0.93, 2.10) 1.40 (0.92,2.13) 1.29 (0.84, 1.99) 1.28 (0.83, 1.98)
No 843 (74.1%) 83 (9.9%) Reference
Model 1 adjusted for age, sex, race, education; Model 2 additionally adjusted for bleeding history, heart failure, carotid artery disease, peripheral arterial disease, hyper-
tension, diabetes, anemia, chronic obstructive lung disease, renal disease and prior implantable cardiac device; Model 3 additionally adjusted for HAS-BLED score, systolic
blood pressure, anticoagulation use, and antiplatelet use.
W. Wang, D. Lessard, J.S. Saczynski et al. IJC Heart & Vasculature 33 (2021) 100739
4
To ensure the efficacy and safety of anticoagulation in the
management of patients with AF, patient participation including
adequate compliance, lifestyle adjustment, and frequent monitor-
ing are required. Impairments in physical, cognitive, and psychoso-
cial domains pose challenges in this regard. However, reports
examining their associations with bleeding [5,15] have been
sporadic. To our knowledge this is the first evaluation of the asso-
ciation between geriatric conditions to bleeding in a contemporary
cohort of older men and women with AF, the majority of whom
were anticoagulated with warfarin and direct oral anticoagulants.
Physical, cognitive, and psychosocial impairments as well as AF
are common in older individuals. There has been increasing aware-
ness about the prognostic value of these impairments in individu-
als with AF [4,16]. For example, depression has been associated
with an increased risk of dying in patients with coexisting AF
and heart failure [17] as well as among patients with AF seen in
a primary care setting [18]. More recent studies have shown a
greater risk of dying among patients with AF who were frail both
in an ambulatory-based AF registry [15] and in patients after
undergoing AF ablation [19]. In addition, social isolation has an
additive risk on mortality to depression [17] in patients with AF
and heart failure. Our findings are in agreement with these previ-
ous reports.
We observed that socially isolated individuals had a more than
2-fold higher risk of dying at one year than those who were well
supported socially. This association was strengthened after
accounting for several comorbidities and patient’s socio-
demographic characteristics. Social isolation has been previously
associated with poor clinical outcomes in patients with acute
myocardial infarction [20] and heart failure [21]. This may be
partly because patients with better social support are more likely
adhere to prescribed medical therapy [22] and embrace lifestyle
modifications such as diet change, exercise, and weight loss [23].
Further studies should examine whether various types of interven-
tions (e.g., telephone check-in, lifestyle coaching, and help in trans-
portation for clinic visit) lessen the detrimental effects of social
isolation among older patients with AF.
The finding that frail and depressed individuals were more
likely to have developed clinically relevant bleeding can facilitate
an open and frank discussion about the risks and benefits associ-
ated with anticoagulation initiation among older patients with
AF. This finding is also consistent with our prior work that depres-
sive symptoms were associated with high perceived anticoagula-
tion burden [16].
More than one-half of individuals in our study developed minor
bleeding. This was much higher than the rate of nuisance bleeding
(14.8 events per 100 person-years) reported in the Outcomes
Registry for Better Informed Treatment of Atrial Fibrillation
(ORBIT-AF) registry [24]. The discrepancy may be explained by
the different ascertainment methods applied. In ORBIT-AF,
nuisance bleeding was ascertained from medical records and
defined as minor bleeding that did not require medical attention.
Our structured questionnaire likely has higher sensitivity in captur-
ing minor bleeding not documented in medical records. Although
minor bleeding is an important patient-reported outcome, it should
not lead to changes in a patient’s anticoagulation plan.
Table 3
Associations between geriatric conditions and 1-year mortality among older adults with atrial fibrillation.
Odds ratio (95% confidence interval)
Death Unadjusted Model 1 Model 2
Cognitive impairment Yes 462 (40.6%) 28 (6.1%) 2.66 (1.42, 4.97) 2.12 (1.05, 4.26) 1.53 (0.74, 3.17)
No 675 (59.4%) 16 (2.4%) Reference
Depression Yes 311 (27.4%) 20 (6.4%) 2.30 (1.25, 4.22) 2.44 (1.31, 4.57) 1.39 (0.64, 3,02)
No 826 (72.7%) 24 (2.9%) Reference
Frailty Yes 151 (13.3%) 16 (10.6%) 4.06 (2.14, 7.69) 3.87 (1.96, 7.65) 1.87 (0.89, 3.92)
No 986 (86.7%) 28 (2.8%) Reference
Hearing impairment Yes 402 (35.4%) 13 (3.2%) 0.76 (0.39, 1.47) 0.59 (0.29, 1.20) 0.60 (0.29, 1.23)
No 735 (64.6%) 31 (4.2%) Reference
Social isolation Yes 148 (13.0%) 11 (7.4%) 2.33 (1.15, 4.71) 2.24 (1.09, 4.60) 2.57 (1.19, 5.55)
No 989 (87.0%) 33 (3.3%) Reference
Vision impairment Yes 294 (25.9%) 14 (4.8%) 1.36 (0.71, 2.59) 1.27 (0.65, 2.49) 1.09 (0.54, 2.19)
No 843 (74.1%) 30 (3.6%) Reference
Model 1 adjusted for age, sex, race, and education. Model 2 additionally adjusted for history of bleeding, heart failure, peripheral vascular disease, hypertension, diabetes,
anemia, lung disease, renal disease, implantable device, and anxiety.
Table 4
Associations between geriatric conditions and clinically relevant bleeding at 1 year among older adults with atrial fibrillation.
Odds ratio (95% confidence interval)
Clinically relevant bleeding* Unadjusted Model 1 Model 2 Model 3
Cognitive impairment Yes 436 (39.7%) 40 (9.2%) 1.53 (0.97, 2.41) 1.49 (0.91, 2.43) 1.50 (0.90, 2.49) 1.50 (0.90, 2.49)
No 663 (60.3%) 41 (6.2%) Reference
Depression Yes 294 (26.8%) 29 (9.9%) 1.59 (0.99, 2.55) 1.75 (1.08, 2.84) 1.82 (1.12, 2.98) 1.79 (1.09, 2.93)
No 805 (73.2%) 52 (6.5%) Reference
Frailty Yes 137 (12.5%) 19 (13.9%) 2.34 (1.35, 4.05) 2. 68 (1.51, 4.75) 2.94 (1.62, 5.35) 2.83 (1.55, 5.17)
No 962 (87.5%) 62 (6.4%) Reference
Hearing impairment Yes 391 (35.6%) 30 (7.7%) 1.07 (0.67, 1.71) 0.99 (0.61, 1.61) 0.99 (0.61, 1.61) 0.96 (0.59, 1.57)
No 708 (64.4%) 51 (7.2%) Reference
Social isolation Yes 139 (12.7%) 15 (10.8%) 1.64 (0.91, 2.96) 1.65 (0.91, 3.00) 1.69 (0.92, 3.08) 1.73 (0.94, 3.17)
No 960 (87.3%) 66 (6.9%) Reference
Vision impairment Yes 284 (25.8%) 27 (9.5%) 1.48 (0.91, 2.40) 1.50 (0.92, 2.45) 1.48 (0.90, 2.42) 1.45 (0.88, 2.38)
No 815 (74.2%) 54 (6.6%) Reference
Model 1 adjusted for age, sex, race; Model 2 additionally adjusted for education, bleeding history, and HASBLED score; Model 3 additionally adjusted for systolic blood
pressure, anticoagulation use, and antiplatelet use.
*Clinically relevant bleeding is defined as self-reported major bleeding, bleeding related death, and clinical related non-major bleeding.
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4. Study strengths and limitations
Our study has several strengths. First, we used validated instru-
ments to assess the presence of several geriatric conditions,
namely cognition, frailty, social support, and presence of depres-
sive symptoms. Our study population is geographically diverse
and contemporary with a balanced prescription of direct oral anti-
coagulants and warfarin. Also, participants have a high degree of
comorbidity, reflecting a ‘real-world’ population one would expect
to see in daily practice and making the results more generalizable.
Also, bleeding events were graded according to the International
Society on Thrombosis scale [14]. Lastly, mortality was systemati-
cally adjudicated from medical records. Several limitations should,
however, be kept in mind in the interpretation of our study results.
Bleeding events were ascertained from scripted interviews with
patients and were not adjudicated frommedical records. Therefore,
the bleeding events could be subjected to recall bias. We planned
to report the adjudicated outcomes in future publications as they
become available. Secondly, the study was not an inception cohor-
t and patients with bleeding complication at the beginning of
anticoagulation may have been lost, thus the bleeding rate may
have been underestimated. Thirdly, quality of anticoagulation
control is important and can be related to bleeding and death. In
fact, adjusting the time in the therapeutic range attenuated
the association between geriatric condition and composite end-
point of bleeding and death. This finding was somewhat expected
as the quality of anticoagulation is more likely to be a mediator
rather than a confounder of the observed association (geriatric
impairment ? poor anticoagulation quality ? more bleeding and
death). Therefore, adjusting for this factor would likely attenuate
the association under study. Because this is an observational study,
we cannot establish causation and residual confounding by other
factors may have affected our study results.
5. Conclusion
Among older patients with AF recruited from the ambulatory
setting, social isolation was associated with an increased risk of
dying over our one-year follow-up period and clinically relevant
bleeding was more common in individuals with depressive symp-
toms and frailty. Assessing physical, cognitive, and psychosocial
limitations in older patients with AF helps identify individuals at
high risk for poor clinical outcomes who may require increased
surveillance or tailored management. It also facilitates risk and
benefit discussions of anticoagulation therapy among older
patients with AF.
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